Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CD34t CAR-T Cells in Adult Patients With CD19 Positive B-ALL
NCT07896213Phase 1Not yet recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Nov 2026
- Primary completion
- Dec 2033
- Countries
- 1
01
Overview
Phase 1, open-label trial in B-cell acute lymphoblastic leukemia (B-ALL) (4 cohorts), sponsored by Medical University of South Carolina. Primary endpoints: Maximum Tolerated Dose at 28 days, Safety Assessment at 28 days and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07896213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07896213.